Low tar cigarettes do not cut lung cancer riskJanuary 10, 2004The risk of lung cancer is no different in people who smoke medium tar cigarettes, low tar cigarettes, or very low tar cigarettes, concludes new research from the United States. Researchers analysed the relation between the tar rating of the brand of cigarette smoked in 1982 and death from lung cancer over six years among 364,239 men and 576,535 women aged 30 years or more. Irrespective of the tar level of their current brand, all current smokers had a far greater risk of lung cancer than people who had never smoked or who had quit. Men and women who smoked very low tar (7 mg or less) and low tar (8-14 mg) brands had risks of lung cancer indistinguishable from those who smoked medium tar (15-21 mg) brands. This pattern did not change after demographic factors, dietary habits, and occupational and medical histories were taken into account. Men and women who smoked non-filtered cigarettes with tar ratings of 22 mg or more had even higher risks of lung cancer. These findings are consistent with other evidence that people smoke low tar cigarettes more intensively, and challenge the assumption that the link between tar rating and lung cancer risk is necessarily linear, say the authors. They suggest that reducing the use of high tar non-filter cigarettes may provide limited public health benefits in those countries where these products are commonly used. | |||||||||||||||||||||
|
Related Lung Cancer Current Events and Lung Cancer News Articles Drop in cancer deaths tied primarily to gains in behavior and screening Improvements in behavior and screening have contributed greatly to the 13 percent decline in cancer mortality since 1990, with better cancer treatments playing a supporting role, according to new research from David Cutler of Harvard University. Stanford blood scanner detects even faint indicators of cancer A team led by Stanford researchers has developed a prototype blood scanner that can find cancer markers in the bloodstream in early stages of the disease, potentially allowing for earlier treatment and dramatically improved chances of survival. Combining targeted therapy drugs may treat previously resistant tumors A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches. Tiny protein provokes healthy bonding between cells In human relationships, a certain "spark" often governs whether we prefer one person to another, and critical first impressions can occur within seconds. A team lead by Johns Hopkins researchers has found that cell-to-cell "friendships" operate in much the same way and that dysfunctional bonding is linked to the spread of cancer. MU study reveals effective anti-tobacco ads should either scare or disgust viewers Now's the perfect time to increase anti-smoking campaigns - Nov. 20 is the American Cancer Society's Great American Smokeout. Iressa proves just as effective as chemotherapy for lung cancer Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side effects, according to an international Phase III clinical trial, led by researchers at The University of Texas M. D. Anderson Cancer Center. Novel 4-drug combination proves safe for lung cancer treatment The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center. The miseries of allergies just may help prevent some cancers, study finds There may be a silver -- and healthy -- lining to the miserable cloud of allergy symptoms: Sneezing, coughing, tearing and itching just may help prevent cancer -- particularly colon, skin, bladder, mouth, throat, uterus and cervix, lung and gastrointestinal tract cancer, according to a new Cornell study. Researchers aim to over-stress already taxed mantle cell lymphoma cells Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them. Researchers describe how chronic inflammation can lead to stomach cancer A multi-center research team, led by Columbia University Medical Center, has uncovered a major contributor to the cause of stomach cancer - the second leading cause of cancer-related mortality in the world. More Lung Cancer Current Events and Lung Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||